Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.

Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS.

J Neurosci. 2011 Feb 9;31(6):2313-20. doi: 10.1523/JNEUROSCI.4717-10.2011.

2.
3.

[Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].

Benek O, Musílek K, Kuca K.

Ceska Slov Farm. 2012 Aug;61(4):144-9. Review. Czech.

PMID:
23251955
4.
5.

Mitochondrial dysfunction and Alzheimer's disease.

Chen X, Stern D, Yan SD.

Curr Alzheimer Res. 2006 Dec;3(5):515-20. Review.

PMID:
17168650
6.

Pathogenic role of mitochondrial [correction of mitochondral] amyloid-beta peptide.

Chen JX, Yan SD.

Expert Rev Neurother. 2007 Nov;7(11):1517-25. Review.

PMID:
17997700
7.

Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?

Borger E, Aitken L, Du H, Zhang W, Gunn-Moore FJ, Yan SS.

Curr Alzheimer Res. 2013 Jan;10(1):21-9. Review.

8.

Amyloid-beta-induced mitochondrial dysfunction.

Chen JX, Yan SD.

J Alzheimers Dis. 2007 Sep;12(2):177-84. Review.

9.

Role of mitochondrial amyloid-beta in Alzheimer's disease.

Chen JX, Yan SS.

J Alzheimers Dis. 2010;20 Suppl 2:S569-78. doi: 10.3233/JAD-2010-100357. Review.

PMID:
20463403
10.

Mitochondrial import and degradation of amyloid-β peptide.

Pinho CM, Teixeira PF, Glaser E.

Biochim Biophys Acta. 2014 Jul;1837(7):1069-74. doi: 10.1016/j.bbabio.2014.02.007. Epub 2014 Feb 18. Review.

11.

Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease.

Reddy PH.

Exp Neurol. 2009 Aug;218(2):286-92. doi: 10.1016/j.expneurol.2009.03.042. Epub 2009 Apr 7. Review.

12.

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Yan SD, Bierhaus A, Nawroth PP, Stern DM.

J Alzheimers Dis. 2009;16(4):833-43. doi: 10.3233/JAD-2009-1030. Review.

13.

Mitochondrial dysfunction: different routes to Alzheimer's disease therapy.

Picone P, Nuzzo D, Caruana L, Scafidi V, Di Carlo M.

Oxid Med Cell Longev. 2014;2014:780179. doi: 10.1155/2014/780179. Epub 2014 Aug 20. Review.

14.

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.

Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD.

Curr Mol Med. 2007 Dec;7(8):735-42. Review.

PMID:
18331231
15.

The organellar peptidasome, PreP: a journey from Arabidopsis to Alzheimer's disease.

Glaser E, Alikhani N.

Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1076-80. doi: 10.1016/j.bbabio.2009.12.016. Epub 2009 Dec 28. Review.

16.

Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide.

Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D.

Biochim Biophys Acta. 2000 Jul 26;1502(1):145-57. Review.

17.

Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationship.

Grimm A, Lim YA, Mensah-Nyagan AG, Götz J, Eckert A.

Mol Neurobiol. 2012 Aug;46(1):151-60. doi: 10.1007/s12035-012-8281-x. Epub 2012 Jun 8. Review.

18.

Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta.

Du H, Yan SS.

Biochim Biophys Acta. 2010 Jan;1802(1):198-204. doi: 10.1016/j.bbadis.2009.07.005. Epub 2009 Jul 16. Review.

19.

Mitochondrial accumulation of APP and Abeta: significance for Alzheimer disease pathogenesis.

Pavlov PF, Hansson Petersen C, Glaser E, Ankarcrona M.

J Cell Mol Med. 2009 Oct;13(10):4137-45. doi: 10.1111/j.1582-4934.2009.00892.x. Epub 2009 Sep 1. Review.

20.

Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?

Reddy PH.

Biochim Biophys Acta. 2013 Jan;1832(1):67-75. doi: 10.1016/j.bbadis.2012.09.003. Epub 2012 Sep 17. Review.

Supplemental Content

Support Center